HP INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (In millions) | |||||||
Nine months ended | |||||||
July 31, 2024 | July 31, 2023 | ||||||
Cash flows from operating activities: | |||||||
Net earnings | $ | 1,869 | $ | 2,289 | |||
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||
Depreciation and amortization | 622 | 638 | |||||
Stock-based compensation expense | 367 | 353 | |||||
Restructuring and other charges | 180 | 416 | |||||
Deferred taxes on earnings | 69 | (774 | ) | ||||
Other, net | (24 | ) | (61 | ) | |||
Changes in operating assets and liabilities, net of acquisitions: | |||||||
Accounts receivable | (447 | ) | 180 | ||||
Inventory | (953 | ) | 364 | ||||
Accounts payable | 1,442 | (1,133 | ) | ||||
Net investment in leases from integrated financing | (123 | ) | (82 | ) | |||
Taxes on earnings | (89 | ) | 354 | ||||
Restructuring and other | (204 | ) | (244 | ) | |||
Other assets and liabilities | (583 | ) | (704 | ) | |||
Net cash provided by operating activities | 2,126 | 1,596 | |||||
Cash flows from investing activities: | |||||||
Investment in property, plant and equipment, net | (439 | ) | (459 | ) | |||
Purchases of available-for-sale securities and other investments | — | (6 | ) | ||||
Maturities and sales of available-for-sale securities and other investments | — | 18 | |||||
Collateral posted for derivative instruments | (60 | ) | (118 | ) | |||
Payment made in connection with business acquisitions, net of cash acquired | (15 | ) | (5 | ) | |||
Net cash used in investing activities | (514 | ) | (570 | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from short-term borrowings with original maturities less than 90 days, net | — | 190 | |||||
Proceeds from debt, net of issuance costs | 266 | 177 | |||||
Payment of debt and associated costs | (153 | ) | (1,654 | ) | |||
Stock-based award activities and others | (67 | ) | (86 | ) | |||
Repurchase of common stock | (1,200 | ) | (100 | ) | |||
Cash dividends paid | (812 | ) | (777 | ) | |||
Collateral returned for derivative instruments | — | (200 | ) | ||||
Settlement of cash flow hedges | — | (3 | ) | ||||
Net cash used in financing activities | (1,966 | ) | (2,453 | ) | |||
Decrease in cash, cash equivalents and restricted cash | (354 | ) | (1,427 | ) | |||
Cash, cash equivalents and restricted cash at beginning of period | 3,232 | 3,145 | |||||
Cash, cash equivalents and restricted cash at end of period | $ | 2,878 | $ | 1,718 |